LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akcijų sąrašas・Exelixis Inc

Exelixis Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

50.11 0.99

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

49.91

Max

50.21

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-34M 210M
Pardavimai	12M 611M
P/E Sektoriaus vid.	16.503 49.701
Pelnas, tenkantis vienai akcijai	0.87
Pelno marža	34.457
Darbuotojai	1,077
EBITDA	15M 258M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	-4.89% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-27

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.3B 13B
Ankstesnė atidarymo kaina	49.12
Ankstesnė uždarymo kaina	50.11

Naujienos nuotaikos

By Acuity

50%

159 / 345 reitingas Healthcare

Exelixis Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-25 08:24; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

2026-05-25 21:22; UTC

Uždarbis

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

2026-05-25 20:50; UTC

Rinkos pokalbiai

Uždarbis

Basic Materials Roundup: Market Talk

2026-05-25 16:20; UTC

Rinkos pokalbiai

Uždarbis

Basic Materials Roundup: Market Talk

2026-05-25 16:01; UTC

Rinkos pokalbiai

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

2026-05-25 14:43; UTC

Rinkos pokalbiai

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

2026-05-25 14:15; UTC

Rinkos pokalbiai

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

2026-05-25 13:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-05-25 12:58; UTC

Rinkos pokalbiai

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

2026-05-25 12:56; UTC

Rinkos pokalbiai

Uždarbis

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

2026-05-25 12:48; UTC

Rinkos pokalbiai

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

2026-05-25 12:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-25 12:34; UTC

Rinkos pokalbiai

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

2026-05-25 12:10; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Delivery Hero's Assets Look Strategic -- Market Talk

2026-05-25 11:00; UTC

Rinkos pokalbiai

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

2026-05-25 10:19; UTC

Rinkos pokalbiai

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

2026-05-25 10:05; UTC

Uždarbis

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

2026-05-25 10:04; UTC

Uždarbis

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

2026-05-25 10:03; UTC

Uždarbis

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

2026-05-25 10:02; UTC

Uždarbis

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

2026-05-25 10:01; UTC

Uždarbis

Tenaga Nasional 1Q Net Up 3.7% on Year

2026-05-25 10:00; UTC

Uždarbis

Tenaga Nasional 1Q Rev Up 6.6% on Year

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional 1Q EPS MYR0.1883

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional 1Q Rev MYR17.1B

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional 1Q Net MYR1.1B

2026-05-25 09:38; UTC

Rinkos pokalbiai

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

2026-05-25 09:33; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-25 09:33; UTC

Rinkos pokalbiai

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

2026-05-25 08:55; UTC

Rinkos pokalbiai

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Akcijų palyginimas

Kainos pokytis

Exelixis Inc Prognozė

Kainos tikslas

By TipRanks

-4.89% į apačią

12 mėnesių prognozė

Vidutinis 47.7 USD -4.89%

Aukščiausias 56 USD

Žemiausias 40 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Exelixis Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Exelixis Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

159 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.